- An Introduction to NAYA Biosciences with CEO Dr.
Daniel Teper
- Managing unprecedented medical innovation in an era of
financial market volatility
- Increasing patient access to breakthrough treatments in
oncology, regenerative medicine, and fertility
SARASOTA, Fla. and AVENTURA, Fla., Oct. 27,
2023 /PRNewswire/ -- INVO Bioscience ("INVO")
and NAYA Biosciences ("NAYA"), two companies which recently signed
a definitive merger agreement, today announced that NAYA CEO Dr.
Daniel Teper will present at Tribe
Public's Webinar Presentation and Q&A Event, titled
"Accelerating Biotech Value Creation"
. The event is scheduled to begin at 8:30AM PST/11:30AM EST on Tuesday, October 31, 2023. To register to join
the complimentary event, please visit the Tribe Public LLC at
NAYAOCT3123.TribePublic.com.
NAYA Biosciences is building a group of agile, disruptive,
high-growth companies dedicated to increasing patient access to
life-transforming treatments in oncology, fertility, and
regenerative medicine. NAYA's capabilities in biology, cell
and gene therapy, and artificial intelligence (AI) provide a
synergistic platform for the accelerated clinical development and
commercialization of these breakthrough treatments.
Dr. Teper is the Founder, Chairman, and Chief Executive Officer
of NAYA Biosciences. He has over 30 years of leadership experience
as a biopharma entrepreneur, corporate executive, and management
consultant.
Previously, Dr. Teper was the Chairman & CEO of Cytovia
Therapeutics, where he remains Chairman of the Board. From 2011 to
2017, he was the CEO of Immune Pharmaceuticals, which he listed on
NASDAQ. He previously served as New
York-based Managing Partner (Head of North America) at Bionest Partners, now
Accenture, where he advised companies on corporate strategy and
business development. He was previously a Partner at ISO Healthcare
Group, now Deloitte, in New York.
Dr. Teper helped drive the accelerated growth of Softwatch, a
pioneer digital health company, as senior vice president of sales
and business development. He also served as global president of
Havas Health, advising companies on global launches of major new
drugs in multiple disease areas. Dr. Teper started his career at
Novartis in Basel and then in the
US, where he held management responsibilities in sales and
marketing and as head of cardiovascular, new product development.
Dr. Teper held general management positions in Europe at GlaxoSmithKline and Sanofi. He was
the co-founder and CEO of Wintec Pharma, a European specialty
pharmaceutical company focused on anti-infectives and dermatology,
which he went on to sell. Dr. Teper co-founded Novagali, an
ophthalmology specialty pharma later listed on EuroNext Paris and
acquired by Japan's Santen.He
holds a Doctor of Pharmacy degree from Paris XI University and an
MBA from INSEAD, where he was the J. Salmon scholar.
Once registered, participants may begin forwarding their
questions for the CEO to Tribe Public
at research@tribepublic.com or share their questions via
the ZOOM chat feature during the event. Tribe Public's Managing
Member, John F. Heerdink, Jr., will
host the event and relay all questions to management.
ABOUT NAYA Biosciences
NAYA Biosciences is building a group of agile, disruptive,
high-growth companies dedicated to increasing patient access to
life-transforming treatments in oncology, fertility, and
regenerative medicine. NAYA's capabilities in biology, cell
and gene therapy, and artificial intelligence (AI) provide a
synergistic platform for the accelerated clinical development and
commercialization of these breakthrough treatments.
NAYA Oncology aims to achieve clinical
proof-of-concept for its two bispecific antibodies acquired from
Cytovia Therapeutics, with the goal of advancing towards
breakthrough outcomes for Hepatocellular Carcinoma and Multiple
Myeloma patients. Clinical trials are expected to start in
2024.
NAYA Fertility aims to increase accessibility to
advanced fertility care through a growing network of INVO-owned and
affiliated clinics and the commercialization of INVO's unique
FDA-cleared INVOcell® device.
NAYA Regenerative Medicine is evaluating the
acquisition of clinic-stage assets aiming to restore biological
function in patients with damaged tissues and organs.
For more information, please
visit www.nayabiosciences.com.
About INVO Bioscience
We are a healthcare services fertility company dedicated to
expanding the assisted reproductive technology ("ART") marketplace
by making fertility care accessible and inclusive to people around
the world. Our commercialization strategy is focused on the opening
of dedicated "INVO Centers" offering the INVOcell® and IVC
procedure (with three centers in North America now
operational), the acquisition of US-based, profitable in vitro
fertilization ("IVF") clinics and the sale and distribution of our
technology solution into existing fertility clinics. Our
proprietary technology, INVOcell®, is a medical device that allows
fertilization and early embryo development to take place in vivo
within the woman's body. This treatment solution is the world's
first intravaginal culture technique for the incubation of oocytes
and sperm during fertilization and early embryo development. We
believe the IVC procedure can deliver comparable results to
traditional IVF and is a more effective treatment than intrauterine
insemination ("IUI"). For more information, please
visit www.invobio.com.
ABOUT TRIBE PUBLIC LLC
Tribe Public LLC is a San Francisco,
CA based organization that hosts complimentary worldwide
webinar & meeting events in the U.S. Tribe's complimentary
events focus on issues that the Tribe members care about with an
emphasis on hosting management teams from publicly traded companies
from all sectors & financial organizations that are seeking to
increase awareness of their products, progress and plans. Tribe
members primarily include Family Offices, Portfolio Managers,
Registered Investment Advisors, Accredited Investors, Sell Side
Analysts, and members of media. Tribe Members are encouraged to
express their interest in speakers they care about and want to
learn from at the Tribe Public website via the Tribe's FREE "Wish
List" process. Visit Tribe Public's Website to learn more:
http://www.tribepublic.com/
Additional Information about the Proposed Merger and Where to
Find It
INVO filed a current report on Form 8-K with the U.S. Securities
and Exchange Commission (the "SEC") regarding the Merger, which
included the Merger Agreement as an exhibit thereto. Closing
of the merger remains subject to key closing conditions as defined
in the merger agreement, including shareholder approval.
Shareholders and others wishing to obtain additional information
regarding the Merger Agreement and the Merger are urged to review
these documents, which are now available at the SEC's website
(https://www.sec.gov).
Safe Harbor Statement
This release may include forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
INVO invokes the protections of the Private Securities Litigation
Reform Act of 1995. All statements regarding INVO's expected future
financial position, results of operations, cash flows, financing
plans, business strategies, products and services, competitive
positions, growth opportunities, plans and objectives of management
for future operations, as well as statements that include words
such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other
similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties, and
contingencies, many of which are beyond INVO's control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
INVO's filings at www.sec.gov. INVO is under no
obligation to (and expressly disclaim any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/free-registration-is-now-open-for-tribe-publics-ceo-and-qa-presentation-webinar-event-accelerating-biotech-value-creation-featuring-naya-biosciences-ceo-dr-daniel-teper-on-tuesday-october-31-2023-301969766.html
SOURCE INVO Bioscience, Inc.